Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment (Q42930179)
Jump to navigation
Jump to search
scientific article published on 20 August 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment |
scientific article published on 20 August 2010 |
Statements
1 reference
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment (English)
1 reference
Cécile Ortholan
1 reference
Jérôme Durivault
1 reference
Jean-Michel Hannoun-Levi
1 reference
Mélanie Guyot
1 reference
Christine Bourcier
1 reference
Damien Ambrosetti
1 reference
Stephen Safe
1 reference
Gilles Pagès
1 reference
20 August 2010
1 reference
1 reference
46
1 reference
16
1 reference
3022-3036
1 reference
Identifiers
1 reference
1 reference